Role of the drug mannitol during operation involving removal of a part of the kidney
Phase 3
- Conditions
- Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis
- Registration Number
- CTRI/2020/06/026081
- Lead Sponsor
- Abhilash Cheriyan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Scheduled for laparoscopic partial nephrectomy at CMC Vellore
Preoperative eGFR > 45 ml per min per m2
Exclusion Criteria
Known allergy to mannitol
Combined major surgery along with partial nephrectomy
Solitary functioning kidney
Patient with poor LV function
Conversion to open.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To establish equivalence of eGFR at 6 months after laparoscopic partial nephrectomy between mannitol group and the placebo group.Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method Compare blood lossTimepoint: Intraoperative;Compare grade 3-5 complications (clavien-dindo)Timepoint: At the time of discharge. Day 3;Compare intraoperative ischemia timeTimepoint: Intraoperative;Difference in eGFR <br/ ><br>Timepoint: Postoperative Day 2 and Day 10